Utilization of intravenous lidocaine infusion for the treatment of refractory chronic pain by Tully, J. et al.
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/348179613
Utilization of Intravenous Lidocaine Infusion for the Treatment of Refractory
Chronic Pain







Some of the authors of this publication are also working on these related projects:
Anesthesia and Intensive Care View project














The University of Arizona
1 PUBLICATION   5 CITATIONS   
SEE PROFILE
All content following this page was uploaded by Farnad Imani on 16 February 2021.
The user has requested enhancement of the downloaded file.
Anesth Pain Med. 2020 December; 10(6):e112290.
Published online 2021 January 2.
doi: 10.5812/aapm.112290.
Review Article
Utilization of Intravenous Lidocaine Infusion for the Treatment of
Refractory Chronic Pain
Janell Tully 1, Jai Won Jung 2, Anjana Patel 2, Alyson Tukan 1, Sameer Kandula 1, Allen Doan 1, Farnad
Imani 3, **, Giustino Varrassi 4, Elyse M. Cornett 5, *, Alan David Kaye 5, Omar Viswanath 5, 6, 7, 8 and
Ivan Urits 5, 9
1College of Medicine-Phoenix, University of Arizona, Phoenix, AZ, USA
2School of Medicine, Georgetown University, Washington, DC, USA
3Pain Research Center, Department of Anesthesiology and Pain Medicine, Iran University of Medical Sciences, Tehran, Iran
4Paolo Procacci Foundation, Roma, Italy
5Department of Anesthesiology, LSU Health Shreveport, Shreveport, LA, USA
6Valley Anesthesiology and Pain Consultants – Envision Physician Services, Phoenix, AZ, USA
7Department of Anesthesiology, College of Medicine-Phoenix, University of Arizona, Phoenix, AZ, USA
8Department of Anesthesiology, School of Medicine, Creighton University, Omaha, NE, USA
9Southcoast Physicians Group Pain Medicine, Southcoast Health, Wareham, MA, USA
*Corresponding author: Department of Anesthesiology, LSU Health Shreveport, Shreveport, LA, USA. Email: ecorne@lsuhsc.edu
**Corresponding author: Pain Research Center, Department of Anesthesiology and Pain Medicine, Iran University of Medical Sciences, Tehran, Iran. Email:
farnadimani@yahoo.com
Received 2020 December 19; Accepted 2020 December 21.
Abstract
Context: Chronic pain accounts for one of the most common reasons patients seek medical care. The financial burden of chronic
pain on health care is seen by direct financial cost and resource utilization. Many risk factors may contribute to chronic pain, but
there is no definite risk. Managing chronic pain is a balance between maximally alleviating symptoms by utilizing a therapeutic
regimen that is safe for long-term use. Currently, non-opioid analgesics, NSAIDs, and opioids are some of the medical treatment
options, but these have numerous adverse effects and may not be the best option for long-term use. However, Lidocaine can achieve
both central and peripheral analgesic effects with relatively few side effects, which may be an ideal compound for managing chronic
pain.
Evidence Acquisition: This is a Narrative Review.
Results: Infusion of lidocaine (2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide), an amino-amide compound, is emerging as a
promising option to fill the therapeutic void for treatment of chronic pain. Numerous studies have outlined dosing protocols for
lidocaine infusion for the management of perioperative pain, outlined below. While there are slight variations in these different
protocols, they all center around a similar dosing regimen to administer a bolus to reach a rapid steady state, followed by infusion
for up to 72 hours to maintain the therapeutic analgesic effects.
Conclusions: Lidocaine may be a promising pharmacologic solution with a low side effect profile that provides central and periph-
eral analgesia. Even though the multifaceted mechanism is not entirely understood yet, lidocaine may be a promising novel remedy
in treating chronic pain in various conditions.
Keywords: Chronic Pain, Lidocaine, Headache, Fibromyalgia, CRPS, Low Back Pain
1. Context
Whether it is accidentally touching a hot stove or a
fresh paper cut, pain elicits an unpleasant sensation. Pain
serves more than just an unpleasant experience and has
been recognized by the American Pain Society as the "fifth
vital sign" (1). When a noxious stimulus creates a feeling
of pain, it serves as a warning signal to the body (2). This
signal can alert a person to potential harm. However, not
all pain is considered adaptive (3). When the pain persists
beyond the healing process, it no longer serves a benefi-
cial purpose (4). Furthermore, persistent pain may lead to
structural and functional changes within the nervous sys-
tem that leads to continuous pain generation and chronic
pain (4, 5).
Chronic pain accounts for one of the most common
reasons individuals seek medical care (6). These visits
increase the health care burden both (7). The presence
of chronic pain impacts every aspect of a person’s abil-
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ity to function (8). Chronic pain has been linked to de-
creased quality of life, increased mobility restrictions, and
daily activities (9). There are also reasonably high rates of
substance-related disorders among patients with chronic
pain, including opioid dependence (10). The increase in
opioid dependence secondary to chronic pain can create
additional burdens on both the patient and the commu-
nity through abuse and addiction (7).
Lidocaine, a suitable alternative for treating visceral
and central pain, can also be useful where drugs are ineffi-
cient or contribute to unpleasant side effects. Intravenous
lidocaine can control chronic pain, such as post-operative
pain, headaches, neurological malignancies, and back
pain (11-14).
1.1. Current Medical Management of Chronic Pain
Managing chronic pain is a balance between maxi-
mally alleviating symptoms while also utilizing a thera-
peutic regimen that is safe for long-term use. In 1986,
the WHO released an "analgesic ladder" to guide clinical
decision-making for cancer-related pain control. This has
become a resource for augmenting therapeutic intensity
in non-cancer pain (15-17). In this model, the ladder’s bot-
tom rung begins with non-opioid treatments, plus ad-
junctive therapy like antidepressants and anxiolytics for
compounding symptoms (16). For pain that outpaces a
low-rung analgesic, the next step escalates to opioids like
codeine for mild to moderate pain (16). The upper-tier uti-
lizes strong opioids like morphine for moderate to severe
pain (16).
The main adverse effects of each medication on the
ladder are outlined below, as these must be weighed in
the therapeutic decision-making process. Among the non-
opioid analgesics, oral NSAIDs carry a risk of gastrointesti-
nal bleeding, renal damage, and cardiovascular effects. Ac-
etaminophen can cause liver toxicity at high doses. The tri-
cyclic antidepressants used as adjunctive therapy for neu-
ropathic pain, like amitriptyline and nortriptyline, carry a
risk of QTc prolongation. Anticonvulsants like pregabalin
and gabapentin are also effective for neuropathic pain but
may cause sedation, peripheral edema and need to be dose-
adjusted for renal impairment. Topical NSAIDs carry the
lowest side effect profile but are only effective for localized
pain (4).
Escalation to opioid therapy also must be used with
caution. Opioids act as agonists on the mu, delta, and
kappa opioid receptors to produce analgesia, and side ef-
fects include sedation, nausea/vomiting, and decreased
gastrointestinal motility leading to constipation (18). Of
greatest concern, opioids can also result in fatal respira-
tory depression, dependence, tolerance, and opioid use
disorder (18). A study in 2014 identified that 34.6% of pa-
tients received opioid prescriptions from two providers,
14.2% of patients from 3 providers, and 11.9% of patients
from four or more providers, which highlights that pre-
scription opioids have played a large role in the progres-
sion of the opioid epidemic (15, 19).
Despite the widespread use of opioids, studies have
found opioids can be counterproductive for managing
chronic pain. Over time, opioids increase the levels of cir-
culating cytokines like interleukin 6, interleukin 1B, and
tumor necrosis factor, which results in paradoxical hy-
peralgesia (15). Neuronal plasticity in the spinal column,
medulla, and hippocampus further contributes to this hy-
peralgesia (1). In addition to the numerous adverse effects
outlined above, this physiologic finding underscores the
need for alternative therapies for chronic pain that are safe
and effective for long-term use.
2. Evidence Acquisition
This is a Narrative Review.
3. Results
3.1. Infusion/Drug Compound
Infusion of lidocaine (2-(diethylamino)-N-(2,6-
dimethylphenyl)acetamide), an amino-amide compound,
is emerging as a promising option to fill the therapeutic
void for treatment of chronic pain (20, 21). Lidocaine was
originally used in 1943 to treat neuropathic burn pain
and has since gained a wide spectrum of uses (1). Because
of its action at voltage-gated sodium channels, lidocaine
is a class 1b antiarrhythmic used to manage pulseless
ventricular tachycardia and ventricular fibrillation (22).
Lidocaine also stabilizes the myocardium by decreas-
ing intracellular sodium and calcium and is therefore
protective in states of ischemia (20). In pain control,
lidocaine is classically considered a local anesthetic but is
now becoming more widely used for systemic analgesia.
Some conditions responsive to lidocaine infusion include
fibromyalgia, diabetic neuropathy, complex regional pain
syndrome, opioid refractory cancer pain, SCI pain, and
postherpetic neuralgia (1). Patients receiving lidocaine
infusion for perioperative analgesia have demonstrated
improved outcomes with less dependence on opioids for
pain control, decreased nausea, decreased ileus rates, and
shorter hospital stay duration (23-25).
Numerous studies have outlined dosing protocols for
lidocaine infusion for the management of perioperative
pain, outlined below. While there are slight variations in
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these different protocols, they all center around a simi-
lar dosing regimen to administer a bolus to reach a rapid
steady state, followed by infusion for up to 72 hours to
maintain the therapeutic analgesic effects. See Table 1.
The dosing patterns outlined above help prevent lido-
caine toxicity, which has occurs at plasma concentrations
greater than 5-8 µg/mL (20). Some of the common pre-
senting symptoms of toxicity include perioral paresthe-
sia, metallic taste, tinnitus, and other neurological symp-
toms such as confusion and seizure (20). Patients receiv-
ing lidocaine infusion should be monitored to develop any
of these symptoms, with subsequent discontinuation of
their infusion if toxicity is suspected.
3.2. Mechanism of Action and Pharmacology
3.2.1. Pharmacokinetics and Half-Life
Lidocaine is a weak base with low water solubility that
distributes systemically to the brain, kidneys, and heart
before reaching less vascularized structures like the skin,
skeletal muscle, and adipose tissue (20). It circulates with
60-80% bound to albumin and α-1 acid glycoprotein and
has a volume of distribution of 91 L kg-1 (20). Plasma clear-
ance of systemic lidocaine is about 10-14 mL kg-1 min-1 (1,
20). Lidocaine equilibrates across the blood-brain barrier
in about 15 minutes to produce central anesthetic effects
(20). The half-life of bolus-dose lidocaine is about 1.5-2
hours, but this increases up to 3 hours in obese patients
and is progressively prolonged with continuous infusion,
reaching up to 6.9 hours in a 48-hour infusion (20).
3.2.2. Mechanisms of Action to Decrease Pain
The most well-documented mechanism of action of li-
docaine is the non-selective inhibition of sodium channels
to dampen the excitability of neurons and decrease the
rate of action potentials (1, 17, 26, 27). Because intravenous
lidocaine can achieve a therapeutic effect at a much lower
concentration than what is needed to block a peripheral
nerve, the mechanism of lidocaine is more complex than
simple sodium channel blockade. It likely is a synergistic
effect of the multiple mechanisms outlined below (20).
In addition to blocking sodium channels, lidocaine
can interact with voltage-gated potassium channels to af-
fect tonic firing neurons (20). Lidocaine also increases in-
tracellular calcium, which modifies T-type calcium chan-
nels involved in pain signaling (20). Inhibition of voltage-
gated hyperpolarization-activated cyclic nucleotide chan-
nels (HCN) in the brain, spinal cord, and dorsal root gan-
glia inhibits the normally excitatory inward current of
cations (20, 27). Synergistically, lidocaine can amplify the
inhibitory effects of glycine channels through allosteric
regulation to further tone down the pain response (27). An-
other site of action is ligand-gated ionotropic glutamate
receptors, where lidocaine reduces the presynaptic release
of excitatory glutamate (27). By decreasing activation of
the kainic acid ionotropic glutamate receptors, lidocaine
reduces gene expression of the cytokines interleukin-1β,
interleukin-6, and tumor necrosis factor-6a that normally
promote inflammation and damage to endothelium (23,
27). Additionally, lidocaine can increase natural killer cell
activity and augment cell-mediated immunity to promote
a strong immune response against potential pathogens
(20).
On a more macroscopic level, each of these mecha-
nisms described above helps to decrease excitability and
diminish neuronal transmpain signals’ neuronal trans-
missionission of pain signals. Lidocaine prevents depolar-
ization of damaged and dysfunctional nerves that are im-
plicated in chronic pain (17). Additionally, lidocaine de-
creases transmission through A-delta and C neural pain
fibers, which decreases visceral pain (1). Lidocaine can
achieve both central and peripheral analgesic effects with
relatively few side effects, making it an ideal compound for
the management of chronic pain.
3.3. Headache
Chronic daily headache (CDH) is a descriptive term
that encompasses many different headaches that occur at
least fifteen days per month for three months or more.
CDH includes chronic tension-type headache, chronic mi-
graine headache, new daily persistent headache, medica-
tion overuse headache, and hemicrania continua (28). In a
retrospective survey of patients with CDH associated with
medication overuse (n = 71), lidocaine infusion at 2 mg/min
for a minimum of 7 days to a maximum of 14 days resulted
in successful withdrawal from the implicated analgesic
medication in 97% of patients. Moreover, at the 6-month
follow-up, 20% of patients reported that their headache
was less severe, and 51% of patients y no longer were experi-
encing chronic daily headaches. Notably, only mild side ef-
fects (seen in 21% of patients) occurred, such as nausea and
hypotension - and they did not lead to the discontinuation
of treatment (29).
The efficacy of intravenous lidocaine is corroborated
by another retrospective survey conducted by Hand et al.
of 19 patients with CDH, all taking codeine or another nar-
cotic. Hand et al. found lidocaine infusion resulted in re-
mission of symptoms in four individuals and a more man-
ageable pattern of headache in six individuals at the six-
month mark. Since complications and adverse effects were
minimal, the study found lidocaine to be safe for manag-
ing severe, intractable CDH (30). Similarly, Kaube et al.
reported that, in 19 patients with CDH, IV lidocaine infu-
sions (2 mg/min) for two days resulted in a discontinua-
tion of pain in 26% of patients and a 50% or greater im-
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Table 1. Bolus Dose, Infusion Rate, and Notes about Lidocaine Infusion
Bolus dose (mg kg-1) Infusion Rate (2 mg kg-1 h-1) Special Notes Citation
1-2 1-2 Administer bolus over 1 minute, and don’t exceed 100mg bolus dose 3
2 0.5-3 1-2 mg kg-1 h-1 is the most common dosing range for continuous infusion 3
1-2 1-2 50% dose reduction every six hours to prevent toxicity 8
0-1.5 1.5-3 – 10
1 0.5-1 Discontinue infusion on postoperative day 2 10
provement in pain for 42% of patients (31). Marmura et al.
found in a retrospective chart review of 68 patients with
CDH and chronic cluster headache (CCH) lidocaine infu-
sions resulted in a 4-point decrease in headache severity,
from 7.9 to 3.9.
Moreover, the treatment was well-tolerated with no
adverse events that required discontinuation of infusions
(32). IV lidocaine may also be a therapeutic option for
chronic daily headache secondary to acoustic neuroma re-
section. Previous studies have shown that headaches are
a frequent postoperative complication of resection, occur-
ring in around 50% of patients, and are particularly dif-
ficult to treat. A case report by Schere and Silberstein
presents a 47-year-old male patient, whose IV lidocaine
treatment of post-acoustic neuroma resection headache
was successful (33). The potential for this form of treat-
ment is further bolstered by the findings of a case series
conducted by Mooney et al. focused on adolescents and
young adults. The study, conducted at Seattle Children’s
Hospital, shows that the use of lidocaine infusions on pedi-
atric patients with chronic headache and other refractory
chronic pain conditions was well-tolerated and resulted in
reductions in self-reported pain scores without the pres-
ence of any serious side effects (34).
Even in rare forms of primary headache, the adminis-
tration of intravenous lidocaine has yielded beneficial re-
sults. In a case series of four patients with short-lasting
unilateral neuralgiform headache attacks with conjuncti-
val injection and tearing (SUNCT), Matharu et al. reported
that lidocaine infused at 1mg/min – 3 mg/min reduced or
completely suppressed headache attacks during the dura-
tion of infusion (35). Similarly, Weng et al. examined var-
ious treatment modalities for two uncommon headache
syndromes: SUNCT and short-lasting unilateral neuralgi-
form headache attacks with cranial autonomic symptoms
(SUNA). Their work found intravenous lidocaine infusions
to be highly efficacious in reducing attacks. Intravenous
lidocaine was used in 15 SUNCT patients, resulting in a re-
duction of 100% of attacks and 9 SUNA patients, resulting
in a reduction of 88% (8 of 9 cases) of attacks.
Conversely, intravenous dihydroergotamine, an agent
that has been used to treat intractable migraines and clus-
ter headaches, did not reduce attacks in either SUNCT or
SUNA patients. In terms of SUNCT patients, 50% did see
a reduction in attacks with greater occipital nerve injec-
tions, although this method had no reliable effect on SUNA
patients. Furthermore, sumatriptan, high-flow oxygen,
placebo-controlled indomethacin injections, dihydroer-
gotamine, and corticosteroids offered little to no help in
both SUNCT and SUNA cases (36).
The inefficacy of intravenous dihydroergotamine in
particular, though, has also been demonstrated by a case
series of 24 patients diagnosed with chronic SUNA or
SUNCT and co-existent chronic migraine and CCH. When
treated with IV dihydroergotamine, 5 of the patients expe-
rienced a significant worsening of their SUNA or SUNCT, 2
developed new-onset SUNA, 16 experienced no benefit, and
one patient reported a slight improvement in symptoms.
However, it is worth noting that intravenous lidocaine was
efficacious in providing relief for the exacerbated symp-
toms of those seven patients who experienced new or wors-
ening SUNCT/SUNA syndromes due to the intravenous di-
hydroergotamine treatment (37).
Despite successful responses to IV lidocaine in patients
with various forms of refractory chronic headache types,
cardiovascular and neurological side effects remain a po-
tential concern. Lidocaine is hepatically metabolized via
the cytochrome P450 3A4 enzyme, and factors such as
liver dysfunction, drug-drug interactions, and CYP3A4 ge-
netic polymorphisms can all alter serum levels (38). Di-
gala et al. present the case of a 52-year-old woman receiv-
ing IV lidocaine infusions for the treatment of refractory
hemicrania continua on several medications, including
gabapentin, metformin, sertraline, and trazodone. After
initially responding well to the infusions, the patient de-
veloped nystagmus, syncope, and bradycardia before asys-
tole occurred with significantly elevated lidocaine concen-
trations (16 mcg/mL). Although the patient recovered after
a few days, this case highlights the importance of using IV
lidocaine judiciously, especially when a patient is on sev-
eral medications, a few of which are metabolized by the
CYP3A4 enzyme (39). Lidocaine levels should be monitored
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carefully and should remain within the therapeutic range
as levels beyond 10mcg/mL, as seen in this patient, are as-
sociated with ventricular arrhythmias (40). See Table 2.
3.4. Fibromyalgia
The American College of Rheumatology defines fi-
bromyalgia (FM) as a widespread chronic pain syndrome
confirmed by the Widespread Pain Index (WPI) and so-
matic Symptom Severity (SS) scale with associated fatigue,
sleep disturbances, psychological distress, and impaired
quality of life (41). Sorensen et al. conducted a double-blind
cohort study that evaluated the effects of intravenous ke-
tamine infusion and lidocaine infusion on FM patients
with central sensitization and secondary hyperalgesia and
observed complete pain relief from ketamine infusion
with moderate pain control with lidocaine infusion (42).
In contrast, Koppert et al. investigated the pain mecha-
nism in FM from multiple pain models and observed me-
chanical hyperalgesia, a peripheral excitation of Aδ and C-
nociceptor, particularly sensitive low-concentration of li-
docaine (43). These findings supported the idea that intra-
venous lidocaine infusion may provide moderate to signif-
icant pain relief in FM’s various pain states.
Several studies demonstrated the efficacy of intra-
venous lidocaine infusion in FM syndrome beyond an ini-
tial treatment or brief series of treatments. Schafranski et
al. evaluated 23 patients in Brazil with FM who received
five consecutive daily infusions of lidocaine (administered
in 500 mL of 0.9% saline solution over two hours) and ob-
served a significant improvement after the fifth infusion
with decreased pain scores and Fibromyalgia Impact Ques-
tionnaire (FIQ) scores (44) This finding is supported by
Vlainich et al., who observed a decrease in both hyperalge-
sia and pain intensity after four weeks of intravenous lido-
caine infusion with amitriptyline; no significant findings
were reported for amitriptyline alone (45). In a case series
reported by Marks et al., three patients with FM had pain re-
lief after starting on intravenous lidocaine infusion. They
made the recommendation to start infusion at 5 mg/kg
over a 1-hour infusion rate with close cardiac monitoring
(41). Wilderman et al. performed a retrospect chart review
to evaluate the effects of increasing lidocaine dose start-
ing at 5 mg/kg of body weight, 7.5 mg/kg, and 7.5 mg/kg
+ 2.5 g of magnesium sulfate and reported the escalating
dose of intravenous lidocaine to 7.5 mg/kg (with or with-
out magnesium sulfate) could safely and effectively reduce
pain with pain relief up to 17 days (46).
3.5. Low Back Pain
Low back pain is a common pain condition with vari-
ous etiologies ranging from acute injuries, musculoskele-
tal abnormalities, and neoplasms. A series of pharma-
cological tests can help identify the different pain cate-
gories in chronic low back pain (CLBP). Sörensen et al. con-
ducted a single-blind placebo-controlled study to evaluate
the pharmacological test and observed intravenous mor-
phine with fentanyl epidural and intravenous lidocaine
with a local anesthetic epidural had a 50% pain reduc-
tion in nociceptive pain and neuropathic pain, respectively
(47). The systemic administration of local anesthetics in
neuropathic pain has been shown to provide clinical anes-
thesia and pain relief, which was supported by Dunbar et
al., who conducted a two-experimental study that evalu-
ated the analgesic mechanism of epidural steroids in re-
ducing pain associated with degenerative spinal disease
(48). There are a few scenarios where intravenous lidocaine
infusion may not provide adequate pain relief for refrac-
tory pain. For instance, a case report by Watanabe et al. dis-
cussed the additional use of the bilateral intrathecal neu-
rolytic block to provide pain control for a patient with ad-
vance sigmoid colon cancer (49). While there is increasing
evidence that validates the use of intravenous lidocaine in-
fusion for low back pain and chronic pain in general, the
analgesic mechanism of lidocaine remains unclear. More
research is warranted to better understand the long-term
efficacy and resultant symptomatic relief from the treat-
ment.
3.6. Complex Regional Pain Syndrome
Complex regional pain syndrome (CRPS) refers to a
chronic pain condition marked by a steady deterioration
of regional pain without the presence of dermatomal dis-
tribution. Until recently, the therapeutics options for CRPS
include systemic and local administration of lidocaine
(50). This finding was based on prior clinical studies and
animal models of neuropathic pain that demonstrated the
selectivity of lidocaine on voltage-gated sodium channels
on primary nociceptive afferent fibers and inhibition of
repetitive depolarization of dorsal root ganglia pain trans-
mission neurons (50, 51).
A single-blind placebo-controlled study conducted by
Scrivani et al. evaluated the effectiveness of intravenous
phentolamine and lidocaine on chronic neurogenic fa-
cial pain and observed no pain relief with the infusion
of phentolamine compared to the favorable analgesic re-
sponse after a single infusion of lidocaine (52). Similar
findings were observed in Wallace et al., who investigated
the effects of intravenous lidocaine infusion with diphen-
hydramine on pain and neurosensory thresholds within
areas with prominent allodynia (53). Results from the
study revealed decreased pain scores to cool stimuli and
spontaneous pain and an increased to hot pain thresh-
old from 44.7°C to 47.9°C (53). This finding supported
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Table 2. A summary of Noteworthy Studies on IV Lidocaine Infusion for Refractory Chronic Headache
Author (Year) Groups Studied and
Intervention
Results and Findings Conclusions
Williams et al.
(2003) (3)
71 patients with CDH
associated with analgesic
medication overuse received
lidocaine infusion at 2 mg/min
for a minimum of 7 days to a
maximum of 14 days.
Successful withdrawal from the implicated
analgesic medication in 97% of patients. 51%
reported they no longer were experiencing
chronic daily headaches and 20% reported
that their headache was less severe.
IV lidocaine seems to be an effective option for individuals
with CDH secondary to medication overuse. Larger controlled




19 patients with CDH, all
taking codeine or another
narcotic agent received
lidocaine infusion at 2 mg/min
for 9 hours up to 12 days.
At the 6 month mark, 4 individuals had
remission of symptoms while 6 individuals
had a more manageable pattern of headache.
IV lidocaine is useful in the management of intractable CDH
secondary to narcotic overuse. As this was a retrospective
study primarily aimed at analyzing the safety of lidocaine, its




19 patients with CDH received
IV lidocaine infusions at
2mg/min for 2 days.
Discontinuation of pain in 26% of patients
and a 50% or greater improvement in pain for
42% of patients.
In individuals who have refractory CDH, these results suggest
that IV lidocaine can be effective in reducing or eliminating
pain. This study is not blinded and does not serve as a trial of
lidocaine; further research would be beneficial in providing
support for the efficacy of IV lidocaine.
Marmura et
al. (2009) (6)
68 patients with CDH and CCH
received IV lidocaine infusions
at 1mg/min for first the 4
hours, then 2mg/min up to
4mg/min based on patient’s
response for 2 to 15 days.
4 point decrease in headache severity, from 7.9
to 3.9, on headache rating scale.
IV lidocaine appears to be a safe and effective option for
reducing the severity of headache pain in patients with CDH
and CCH. Further research is required to better understand
the sole effect of lidocaine (by removing concomitant
medications). Additionally, work with lower doses and
shorter lengths of infusions should be done to analyze




15 SUNCT patients and 9 SUNA
patients, received IV lidocaine
infusions.
Reduction of 100% of attacks in SUNCT
patients and 88% of attacks in SUNA patients.
These results suggest that IV lidocaine infusions can be highly
efficacious in reducing attacks in the two distinct and rare
conditions SUNCT and SUNA - and offers directions for new
work to help treat these difficult conditions.
Matharu et al.
(2004) (9)
4 patients with SUNCT
received IV lidocaine infusions
at 1mg/min - 3mg/min.
Reduced or completely suppressed headache
attacks during the duration of infusion.
IV lidocaine infusions are useful for the acute management of
SUNCT symptoms but did not provide lasting pain relief after
infusions were stopped. Randomized, double-blind,






resection headache received IV
lidocaine infusions at
1mg/min - 3mg/min.
1 year post lidocaine infusion, headache
frequency reduced to once every two weeks.
IV lidocaine may be a potential treatment option for
individuals with chronic headache secondary to a
post-acoustic neuroma resection. More studies are needed to




15 Adolescents and young
adults with chronic headache
and other refractory chronic
pain conditions received IV
lidocaine infusions at 40–60
mcg/kg/minute for 2 or 6
hours repeated at an interval
of 4 weeks.
Mean reduction in pain scores of 1.7 for
individuals with chronic headache and a
statistically significant improvement in scores
when the pain intensity was 6 or more to
begin with.
IV lidocaine appears to be effective in reducing pain levels in
young adults with chronic headache and other refractory
chronic pain conditions particularly when the initial pain is
worse. RCTs will be needed to definitively establish the






continua received IV lidocaine
infusions at 1mg/min on day 1
and 2 mg/min on day 2.
On day 3 the patient experienced pulseless
electrical activity and asystole. Lidocaine
levels found to be 16 mcg/mL.
IV lidocaine must be used cautiously, especially when a
patient is taking several other medications, as drug-drug
interactions can occur. Elevated lidocaine levels, as seen in




24 patients diagnosed with
chronic SUNA or SUNCT and
co-existent chronic migraine
and CCH received IV
dihydroergotamine.
5 of the patients experienced a significant
worsening of their SUNA or SUNCT, 2
developed new onset SUNA. IV lidocaine
successfully suppressed the exacerbations
induced by IV dihydroergotamine.
IV dihydroergotamine appears to have no benefit in
SUNCT/SUNA and may exacerbate symptoms. IV lidocaine,
however, was efficacious in providing relief for the 7 patients
that experienced new or worsening symptoms.
Schwartzman et al., who evaluated the effects from 5-day
continuous intravenous lidocaine infusion (2 g lidocaine
in 250 mL of 5% dextrose) in CRPS patients with severe re-
fractory pain and observed a significant decrease in me-
chanical and thermal allodynia after one month with mod-
erate improvements remained after six months (50). This
finding, along with other studies, supported the potential
long-term pain relief from chronic intravenous lidocaine
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infusion for chronic pain management in CRPS. However,
a randomized, double-blind study conducted by Kim et al.
reports a short-term pain control after pain relief at the
four-week follow-up was not observed even after four con-
secutive lidocaine infusions (54).
Overall, most studies conclude that there are minimal,
nonspecific adverse effects associated with intravenous li-
docaine infusion, including nausea, fatigue, bradycardia,
and hypotension (50). However, a case report by Leong
et al. described a 44-year-old male with CRPS who devel-
oped sudden onset of mood changes, severe anxiety, and
psychotic reactions shortly after receiving lidocaine infu-
sion (55). This finding is believed to be secondary to pa-
tients with a predominant affective component or limbi-
cally augmented pain syndrome that may not respond to
lidocaine infusion or develop behavioral disturbances (55).
While studies support the use of intravenous lidocaine in-
fusion for refractory pain management in CRPS, there is a
need for additional randomized multicentered clinical tri-
als with a larger sample size and longer follow-up period to
make further conclusions (50, 54, 55).
4. Conclusions
A significant percentage of the population suffers from
chronic pain, and the drugs patients take may be sub-
optimal for long-term use. Lidocaine may be a promis-
ing pharmacological approach with a low side-effect pro-
file offering central and peripheral analgesia. Lidocaine
is also associated with significantly reduced chronic daily
headaches. Intravenous infusions showed mild to substan-
tial relief for fibromyalgia pain and complex regional pain
syndrome (CRPS), and low back pain. Although the multi-
faceted mechanism is not yet fully known, lidocaine can be
a promising novel treatment in treating chronic pain un-
der different conditions.
Footnotes
Authors’ Contribution: Study concept and design: JT JWJ
AP AT SK analysis and interpretation of data: AD FI GV EMC
drafting of the manuscript: ADK OV IU critical revision of
the manuscript for important intellectual content: JT JWJ
AP AT SK statistical analysis: AD FI GV EMC ADK OV IU.
Conflict of Interests: None declared.
Funding/Support: None declared.
References
1. Kandil E, Melikman E, Adinoff B. Lidocaine Infusion: A Promising
Therapeutic Approach for Chronic Pain. J Anesth Clin Res. 2017;8(1).
doi: 10.4172/2155-6148.1000697. [PubMed: 28239510]. [PubMed Cen-
tral: PMC5323245].
2. Chapman CR, Vierck CJ. The Transition of Acute Postoperative Pain
to Chronic Pain: An Integrative Overview of Research on Mecha-
nisms. J Pain. 2017;18(4):359 e1–359 e38. doi: 10.1016/j.jpain.2016.11.004.
[PubMed: 27908839].
3. Woolf CJ, American College of P, American Physiological S. Pain:
moving from symptom control toward mechanism-specific phar-
macologic management. Ann Intern Med. 2004;140(6):441–51. doi:
10.7326/0003-4819-140-8-200404200-00010. [PubMed: 15023710].
4. Fornasari D. Pain Mechanisms in Patients with Chronic Pain. Clin Drug
Investig. 2012;32:45–52. doi: 10.2165/11630070-000000000-00000.
5. Aronoff GM. What Do We Know About the Pathophysiology of
Chronic Pain? Implications for Treatment Considerations. Med
Clin North Am. 2016;100(1):31–42. doi: 10.1016/j.mcna.2015.08.004.
[PubMed: 26614717].
6. Wang D. Opioid Medications in the Management of Chronic Abdomi-
nal Pain. Curr Pain Headache Rep. 2017;21(9):40. doi: 10.1007/s11916-017-
0640-x. [PubMed: 28791598].
7. Tawfic Q, Kumar K, Pirani Z, Armstrong K. Prevention of chronic post-
surgical pain: the importance of early identification of risk factors.
J Anesth. 2017;31(3):424–31. doi: 10.1007/s00540-017-2339-x. [PubMed:
28349202].
8. Turk DC, Okifuji A. Psychological factors in chronic pain: Evolu-
tion and revolution. J Consult Clin Psychol. 2002;70(3):678–90. doi:
10.1037/0022-006x.70.3.678.
9. Duenas M, Ojeda B, Salazar A, Mico JA, Failde I. A review of chronic
pain impact on patients, their social environment and the health care
system. J Pain Res. 2016;9:457–67. doi: 10.2147/JPR.S105892. [PubMed:
27418853]. [PubMed Central: PMC4935027].
10. Martel MO, Shir Y, Ware MA. Substance-related disorders: A review
of prevalence and correlates among patients with chronic pain.
Prog Neuropsychopharmacol Biol Psychiatry. 2018;87(Pt B):245–54. doi:
10.1016/j.pnpbp.2017.06.032. [PubMed: 28669582].
11. Soleimanpour H, Hassanzadeh K, Vaezi H, Golzari SE, Esfanjani RM,
Soleimanpour M. Effectiveness of intravenous lidocaine versus intra-
venous morphine for patients with renal colic in the emergency de-
partment. BMC Urol. 2012;12:13. doi: 10.1186/1471-2490-12-13. [PubMed:
22559856]. [PubMed Central: PMC3508963].
12. Soleimanpour H, Hassanzadeh K, Mohammadi DA, Vaezi H, Esfan-
jani RM. Parenteral lidocaine for treatment of intractable renal colic:
a case series. J Med Case Rep. 2011;5:256. doi: 10.1186/1752-1947-5-256.
[PubMed: 21714904]. [PubMed Central: PMC3141707].
13. Golzari SE, Soleimanpour H, Rahmani F, Zamani Mehr N, Safari S,
Heshmat Y, et al. Therapeutic approaches for renal colic in the
emergency department: a review article. Anesth Pain Med. 2014;4(1).
e16222. doi: 10.5812/aapm.16222. [PubMed: 24701420]. [PubMed Cen-
tral: PMC3961032].
14. Ghojazadeh M, Sanaie S, Parsian Z, Najafizadeh R, Soleimanpour H.
Use of Lidocaine for Pain Management in the Emergency Medicine:
A Systematic Review and Meta-Analysis. Pharm Sci. 2019;25(3):177–83.
doi: 10.15171/ps.2019.48.
15. Yang J, Bauer BA, Wahner-Roedler DL, Chon TY, Xiao L. The Modified
WHO Analgesic Ladder: Is It Appropriate for Chronic Non-Cancer
Pain? J Pain Res. 2020;13:411–7. doi: 10.2147/JPR.S244173. [PubMed:
32110089]. [PubMed Central: PMC7038776].
16. WHO. WHO’s cancer pain ladder for adults. 2013. Available from:
https://www.mims.co.uk/pain-ladder-cancer-pain-relief-
adults/pain/article/1056346.
17. Eipe N, Gupta S, Penning J. Intravenous lidocaine for acute pain:
an evidence-based clinical update. BJA Educ. 2016;16(9):292–8. doi:
10.1093/bjaed/mkw008.
18. Pathan H, Williams J. Basic opioid pharmacology: an update. Br J Pain.
2012;6(1):11–6. doi: 10.1177/2049463712438493. [PubMed: 26516461].
[PubMed Central: PMC4590096].
Anesth Pain Med. 2020; 10(6):e112290. 7
Tully J et al.
19. Reid MC, Eccleston C, Pillemer K. Management of chronic pain in
older adults. BMJ. 2015;350:h532. doi: 10.1136/bmj.h532. [PubMed:
25680884]. [PubMed Central: PMC4707527].
20. Estebe JP. Intravenous lidocaine. Best Pract Res Clin Anaesthesiol.
2017;31(4):513–21. doi: 10.1016/j.bpa.2017.05.005. [PubMed: 29739540].
21. Yousefshahi F, Predescu O, Francisco Asenjo J. The Efficacy of Systemic
Lidocaine in the Management of Chronic Pain: A Literature Review.
Anesth Pain Med. 2017;7(3). doi: 10.5812/aapm.44732.
22. Mayhew A, Argáez C. Intravenous Lidocaine for Chronic Pain: A Review of
the Clinical Effectiveness and Guidelines. Ottawa (ON): Canadian Agency
for Drugs and Technologies in Health; 2018.
23. Dunn LK, Durieux ME. Perioperative Use of Intra-
venous Lidocaine. Anesthesiology. 2017;126(4):729–37. doi:
10.1097/ALN.0000000000001527. [PubMed: 28114177].
24. Zaman B, Hojjati Ashrafi S, Seyed Siamdoust S, Hassani V, Mohamad
Taheri S, Noorizad S. The Effect of Ketamine and Dexamethasone
in Combination with Lidocaine on the Onset and Duration of Ax-
illary Block in Hand and Forearm Soft Tissue Surgery. Anesth Pain
Med. 2017;7(5). e15570. doi: 10.5812/aapm.15570. [PubMed: 29696115].
[PubMed Central: PMC5903223].
25. Akhondzadeh R, Rashidi M, Gousheh M, Olapour A, Baniahmad A.
The Effect of Adding Dexmedetomidine as an Adjuvant to Lido-
caine in Forearm Fracture Surgeries by Supraclavicular Block Pro-
cedure Under Ultrasound-Guided. Anesth Pain Med. 2018;8(4). doi:
10.5812/aapm.74355.
26. Lauretti GR. Mechanisms of analgesia of intravenous lido-
caine. Rev Bras Anestesiol. 2008;58(3):280–6. doi: 10.1590/s0034-
70942008000300011. [PubMed: 19378524].
27. Yang X, Wei X, Mu Y, Li Q, Liu J. A review of the mechanism of the
central analgesic effect of lidocaine. Medicine (Baltimore). 2020;99(17).
e19898. doi: 10.1097/MD.0000000000019898. [PubMed: 32332666].
[PubMed Central: PMC7440315].
28. Cho SJ, Chu MK. Risk factors of chronic daily headache or chronic mi-
graine. Curr Pain Headache Rep. 2015;19(1):465. doi: 10.1007/s11916-014-
0465-9. [PubMed: 25416458].
29. Williams DR, Stark RJ. Intravenous lignocaine (lidocaine) infusion
for the treatment of chronic daily headache with substantial med-
ication overuse. Cephalalgia. 2003;23(10):963–71. doi: 10.1046/j.1468-
2982.2003.00623.x. [PubMed: 14984229].
30. Hand PJ, Stark RJ. Intravenous lignocaine infusions for severe chronic
daily headache. Med J Aust. 2000;172(4):157–9. doi: 10.5694/j.1326-
5377.2000.tb125538.x. [PubMed: 10772585].
31. Kaube H, Hoskin KL, Goadsby PJ. Lignocaine and headache: an elec-
trophysiological study in the cat with supporting clinical observa-
tions in man. J Neurol. 1994;241(7):415–20. doi: 10.1007/BF00900958.
[PubMed: 7931441].
32. Rosen N, Marmura M, Abbas M, Silberstein S. Intravenous lidocaine
in the treatment of refractory headache: a retrospective case se-
ries. Headache. 2009;49(2):286–91. doi: 10.1111/j.1526-4610.2008.01281.x.
[PubMed: 19222600].
33. Schere D, Silberstein SD. Intravenous lidocaine infusion for the
treatment of post-acoustic neuroma resection headache: a case re-
port. Headache. 2009;49(2):302–3. doi: 10.1111/j.1526-4610.2008.01145.x.
[PubMed: 18549411].
34. Mooney JJ, Pagel PS, Kundu A. Safety, tolerability, and short-term effi-
cacy of intravenous lidocaine infusions for the treatment of chronic
pain in adolescents and young adults: a preliminary report. Pain Med.
2014;15(5):820–5. doi: 10.1111/pme.12333. [PubMed: 24423053].
35. Matharu MS, Cohen AS, Goadsby PJ. SUNCT syndrome respon-
sive to intravenous lidocaine. Cephalalgia. 2004;24(11):985–92. doi:
10.1111/j.1468-2982.2004.00886.x. [PubMed: 15482363].
36. Weng HY, Cohen AS, Schankin C, Goadsby PJ. Phenotypic and
treatment outcome data on SUNCT and SUNA, including a ran-
domised placebo-controlled trial. Cephalalgia. 2018;38(9):1554–63.
doi: 10.1177/0333102417739304. [PubMed: 29096522]. [PubMed Central:
PMC6077870].
37. Lambru G, Shanahan P, Matharu M. Exacerbation of SUNCT
and SUNA syndromes during intravenous dihydroergotamine
treatment: A case series. Cephalalgia. 2015;35(12):1115–24. doi:
10.1177/0333102415570495. [PubMed: 25667300].
38. Bill TJ, Clayman MA, Morgan RF, Gampper TJ. Lidocaine metabolism
pathophysiology, drug interactions, and surgical implications. Aes-
thet Surg J. 2004;24(4):307–11. doi: 10.1016/j.asj.2004.05.001. [PubMed:
19336170].
39. Digala LP, Lucchese S. IV Lidocaine Infusion Leading to the Toxic Levels
in Serum Causing Asystole - A Case Report. Headache. 2020;60(1):269–
70. doi: 10.1111/head.13699. [PubMed: 31743428].
40. Kramer ME, Holtan EE, Ives AL, Wall RT. Perioperative Intravenous
Lidocaine Infusion Adverse Reaction: A Case Report. A A Pract.
2019;13(3):96–8. doi: 10.1213/XAA.0000000000001002. [PubMed:
30920426].
41. Marks DM, Newhouse A. Durability of Benefit From Repeated Intra-
venous Lidocaine Infusions in Fibromyalgia Patients: A Case Series
and Literature Review. Prim Care Companion CNS Disord. 2015;17(5).
doi: 10.4088/PCC.15br01804. [PubMed: 26835161]. [PubMed Central:
PMC4732305].
42. Sorensen J, Bengtsson A, Backman E, Henriksson KG, Bengts-
son M. Pain analysis in patients with fibromyalgia. Effects of
intravenous morphine, lidocaine, and ketamine. Scand J Rheuma-
tol. 1995;24(6):360–5. doi: 10.3109/03009749509095181. [PubMed:
8610220].
43. Koppert W, Zeck S, Sittl R, Likar R, Knoll R, Schmelz M. Low-dose li-
docaine suppresses experimentally induced hyperalgesia in humans.
Anesthesiology. 1998;89(6):1345–53. doi: 10.1097/00000542-199812000-
00011. [PubMed: 9856708].
44. Schafranski MD, Malucelli T, Machado F, Takeshi H, Kaiber F, Schmidt
C, et al. Intravenous lidocaine for fibromyalgia syndrome: an open
trial. Clin Rheumatol. 2009;28(7):853–5. doi: 10.1007/s10067-009-1137-8.
[PubMed: 19263182].
45. Vlainich R, Issy AM, Gerola LR, Sakata RK. Effect of intravenous lido-
caine on manifestations of fibromyalgia. Pain Pract. 2010;10(4):301–5.
doi: 10.1111/j.1533-2500.2010.00362.x. [PubMed: 20230454].
46. Wilderman I, Pugacheva O, Perelman VS, Wansbrough MCT, Voznyak
Y, Zolnierczyk L. Repeated Intravenous Lidocaine Infusions for
Patients with Fibromyalgia: Higher Doses of Lidocaine Have a
Stronger and Longer-Lasting Effect on Pain Reduction. Pain Med.
2020;21(6):1230–9. doi: 10.1093/pm/pnz251. [PubMed: 31621870].
47. Sorensen J, Kalman S, Tropp H, Bengtsson M. Can a pharmacological
pain analysis be used in the assessment of chronic low back pain? Eur
Spine J. 1996;5(4):236–42. doi: 10.1007/BF00301326. [PubMed: 8886735].
48. Dunbar SA, Manikantan P, Philip J. Epidural Infusion Pressure in De-
generative Spinal Disease Before and After Epidural Steroid Therapy.
Anesth Analg. 2002;94(2):417–20. doi: 10.1213/00000539-200202000-
00036.
49. Watanabe A, Yamakage M. Intrathecal neurolytic block in a pa-
tient with refractory cancer pain. J Anesth. 2011;25(4):603–5. doi:
10.1007/s00540-011-1141-4. [PubMed: 21479833].
50. Schwartzman RJ, Patel M, Grothusen JR, Alexander GM. Efficacy of
5-day continuous lidocaine infusion for the treatment of refractory
complex regional pain syndrome. Pain Med. 2009;10(2):401–12. doi:
10.1111/j.1526-4637.2009.00573.x. [PubMed: 19284488].
51. Leffler A, Reiprich A, Mohapatra DP, Nau C. Use-dependent block by
lidocaine but not amitriptyline is more pronounced in tetrodotoxin
(TTX)-Resistant Nav1.8 than in TTX-sensitive Na+ channels. J Pharmacol
Exp Ther. 2007;320(1):354–64. doi: 10.1124/jpet.106.109025. [PubMed:
17005919].
52. Scriveni SJ, Chaudry A, Maciewicz RJ, Keith DA. Chronic neurogenic fa-
cial pain: lack of response to intravenous phentolamine. J Orofac Pain.
1999;13(2).
53. Wallace MS, Ridgeway BM, Leung AY, Gerayli A, Yaksh TL.
Concentration-effect relationship of intravenous lidocaine on the
8 Anesth Pain Med. 2020; 10(6):e112290.
Tully J et al.
allodynia of complex regional pain syndrome types I and II. Anesthe-
siology. 2000;92(1):75–83. doi: 10.1097/00000542-200001000-00017.
[PubMed: 10638902].
54. Kim YC, Castaneda AM, Lee CS, Jin HS, Park KS, Moon JY. Efficacy
and Safety of Lidocaine Infusion Treatment for Neuropathic Pain: A
Randomized, Double-Blind, and Placebo-Controlled Study. Reg Anesth
Pain Med. 2018;43(4):415–24. doi: 10.1097/AAP.0000000000000741.
[PubMed: 29381569].
55. Leong MS, Solvason HB. Case report: limbic system activation by intra-
venous lidocaine in a patient with a complex regional pain syndrome
and major depression. Pain Med. 2000;1(4):358–61. doi: 10.1046/j.1526-
4637.2000.00038.x. [PubMed: 15101882].
Anesth Pain Med. 2020; 10(6):e112290. 9
View publication stats
